News: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

1.55USD
9 Feb 2016
Change (% chg)

-- (--)
Prev Close
$1.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
216,918
52-wk High
$4.80
52-wk Low
$1.11

Search Stocks
Select another date:

Thu, Jan 7 2016

Sequenom to cut jobs; seeks liquid biopsy test partners

Genetic testing company Sequenom Inc said on Thursday it will cut 110 jobs, or about 20 percent of its workforce, and will seek partners to commercialize its liquid biopsy test.

UPDATE 1-Sequenom to cut jobs; seeks liquid biopsy test partners

Jan 7 Genetic testing company Sequenom Inc said on Thursday it will cut 110 jobs, or about 20 percent of its workforce, and will seek partners to commercialize its liquid biopsy test.

Sequenom to cut jobs, divest North Carolina operations

Jan 7 Diagnostic device maker Sequenom Inc said on Thursday it will cut 110 jobs, or about 20 percent of its workforce, and divest its North Carolina operations.

U.S. court rejects Sequenom bid to restore prenatal DNA test patent

NEW YORK A U.S. appeals court refused on Wednesday to reconsider its decision invalidating a Sequenom Inc prenatal DNA test patent, a decision that could put in doubt the validity of a wide range of medical and biotechnology patents.

U.S. court rejects Sequenom bid to restore prenatal DNA test patent

NEW YORK A U.S. appeals court refused on Wednesday to reconsider its decision invalidating a Sequenom Inc prenatal DNA test patent, a decision that could put in doubt the validity of a wide range of medical and biotechnology patents.

UPDATE 2-U.S. court rejects Sequenom bid to restore prenatal DNA test patent

NEW YORK, Dec 2 A U.S. appeals court refused on Wednesday to reconsider its decision invalidating a Sequenom Inc prenatal DNA test patent, a decision that could put in doubt the validity of a wide range of medical and biotechnology patents.

U.S. appeals court rejects Sequenom bid to restore prenatal DNA test patent

NEW YORK, Dec 2 In a key decision that could put in doubt the validity of a wide swath of medical and biotechnology patents, a U.S. appeals court on Wednesday refused to reconsider an earlier decision invalidating a Sequenom Inc prenatal DNA test patent, despite conceding it was a "valuable contribution to science."

Select another date:
Search Stocks